Latest news

Search
Categories
News archive

Interim Report Q2 2024 Nanologica AB (publ)

5 July, 2024

FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671) and for the half-year to SEK -27,860 thousand (-26,764) Earnings per share before and after dilution were SEK -0.25 (-0.41)

Read more »

CEO Comment Q2 2024

5 July, 2024

We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger

Read more »

Nanologica Receives Order for NLAB Saga of approx SEK 2 Million

20 June, 2024

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production. “In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for

Read more »

The Production of NLAB Saga® Stabilizes 

18 June, 2024

Nanologica has now approved a number of normal-sized batches from the large-scale production of the company’s silica for preparative chromatography, NLAB Saga®. Scaling up to large-scale production of silica at the contract manufacturer Sterling Pharma Solutions has been fraught with several challenges such as loss of material, which has previously been communicated. Although a couple of challenges remain, the company has now for the first time completed several large production batches in a row, which

Read more »